In a systematic review of 53 patients with Xp11 tRCC, 33% of the patients showed an objective response to VEGFR-targeted and/or mTOR inhibitor treatment. This evidence concerns the gene MTOR and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.